ArticleGenes & cancer2010
DNA demethylating antineoplastic strategies: a comparative point of view.
Article in Genes & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Targeting the epigenome with advanced delivery strategies for epigenetic modulators.Bioengineering & translational medicine · 2025Review
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.Genes & diseases · 2024Review
- Predicting gene expression changes upon epigenomic drug treatment.F1000Research · 2023Article
- DNA Methyltransferases: From Evolution to Clinical Applications.International journal of molecular sciences · 2022Review
- Hydralazine augmented ultrasound hyperthermia for the treatment of hepatocellular carcinoma.Scientific reports · 2021Article
- Global methylation and promoter-specific methylation of theExperimental and therapeutic medicine · 2017Article
- Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.Oncotarget · 2016Review
- Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells.Genetics research international · 2016Article
- Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.Journal of neuro-oncology · 2016Article
- HEDD: the human epigenetic drug database.Database : the journal of biological databases and curation · 2016Article
- miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.Molecular cancer · 2015Article
- Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells.In vitro cellular & developmental biology. Animal · 2015Article
- Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.Expert opinion on therapeutic targets · 2013Review
- Trials with 'epigenetic' drugs: an update.Molecular oncology · 2012Review
- Cancer epigenetics: a brief review.ILAR journal · 2012Review
- Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase.Journal of computer-aided molecular design · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the involvement of genetic alterations in neoplastic cell transformation, it is increasingly evident that abnormal epigenetic patterns, such as those affecting DNA methylation and histone posttranslational modifications (PTMs), play an essential role in the early stages of tumor development. This finding, together with the evidence that epigenetic changes are reversible, enabled the development of new antineoplastic therapeutic approaches known as epigenetic therapies. Epigenetic modifications are involved in the control of gene expression, and their aberrant distribution is thought to participate in neoplastic transformation by causing the deregulation of crucial cellular pathways. Epigenetic drugs are able to revert the defective gene expression profile of cancer cells and, consequently, reestablish normal molecular pathways. Considering the emerging interest in epigenetic therapeutics, this review focuses on the approaches affecting DNA methylation, evaluates novel strategies and those already approved for clinical use, and compares their therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.